Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747 | 0.92 | MMP8 (0.58) | MMP8MAPK1MEN1S1PR4LMNA | |
| SCHEMBL5326604 | 0.87 | MMP8 (0.53) | MMP8MEN1LMNAMAPTKMT2A | |
| SCHEMBL2050344 | 0.87 | MMP8 (0.53) | MMP8MAPK1MEN1MAPTKMT2A | |
| SCHEMBL534123 | 0.86 | MMP8 (0.52) | MMP8MAPK1MEN1S1PR4LMNA | |
| SCHEMBL7696784 | 0.85 | ESR1 (0.51) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL1867578 | 0.84 | ACACB (0.49) | MEN1KMT2AMMEACACBLDHA | |
| SCHEMBL901733 | 0.84 | EPHX2 (0.50) | MMP8LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL2429506 | 0.84 | PPARG (0.50) | MMP8MAPK1MEN1LMNAMAPT | |
| SCHEMBL3764833 | 0.84 | MMP8 (0.50) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL856250 | 0.83 | MMP8 (0.69) | MMP8MAPK1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240376113-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| US-12091412-B2 | Heterocyclic inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2021257614-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257614-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20140139786-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2011114148-A1 | 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2007144625-A1 | 2-OXO-2H-CHROMENE COMPOUNDS | ARGENTA DISCOVERY LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | MMP8 791/4885MAPK1 910/4885MEN1 1649/4885 |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | MMP8 791/4885MAPK1 910/4885MEN1 1649/4885 |
| US-20240376113-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | MMP8 791/4885MAPK1 910/4885MEN1 1649/4885 |
| US-12091412-B2 | Heterocyclic inhibitors of ENPP1 | ENPP1, ENPP3, ENPP2 | MMP8 791/4885MAPK1 910/4885MEN1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.